Atenolol is a beta-blocker that is used to treat high blood pressure, angina, and other heart conditions. It works by blocking the action of certain natural chemicals in the body, such as epinephrine, that affect the heart and blood vessels. While it is a commonly prescribed drug, it can have side effects, such as fatigue, depression, and difficulty sleeping. For this reason, many doctors are now exploring the potential benefits of low-dose atenolol, which is typically prescribed at 25 mg. In this article, we will explore the potential benefits of low-dose atenolol and discuss whether 25 mg is enough to provide the desired results.
Atenolol is a beta-blocker that is used to treat high blood pressure, angina, and other heart conditions. It works by blocking the action of certain natural chemicals in the body, such as epinephrine, that affect the heart and blood vessels. By blocking these chemicals, atenolol can help to reduce blood pressure and reduce the workload on the heart. It is typically prescribed as a tablet or capsule, and the usual dose is 50 mg a day, taken in divided doses.
Low-dose atenolol, typically prescribed at 25 mg, can provide many of the same benefits as the standard dose. Studies have shown that low-dose atenolol can be just as effective at reducing blood pressure as the standard dose, and it may even be more effective in some cases. Low-dose atenolol can also reduce the risk of side effects, such as fatigue, depression, and difficulty sleeping.
Low-dose atenolol may be an appropriate option for some patients. It may be particularly beneficial for those who are at risk of side effects from the standard dose, such as the elderly or those with other health conditions. It may also be beneficial for those who are unable to take the standard dose due to other medications they are taking. However, it is important to speak to a doctor before taking any medication, as some medications may interact with atenolol.
While low-dose atenolol can provide many of the same benefits as the standard dose, there are some potential risks to consider. Low-dose atenolol may not be as effective at reducing blood pressure as the standard dose, and it may not be suitable for some patients.
Low-dose atenolol, typically prescribed at 25 mg, can provide many of the same benefits as the standard dose. It can be just as effective at reducing blood pressure, and it may even be more effective in some cases. Low-dose atenolol may be an appropriate option for some patients, but it is important to speak to a doctor before taking any medication, as some medications may interact with atenolol. There are also some potential risks to consider, such as the fact that it may not be as effective as the standard dose.
1.
NEJM: Fluorescent guide can aid in the detection of tumors that are still present after breast cancer surgery.
2.
In a randomized trial, the kinder, gentler regimen for classical Hodgkin wins out.
3.
FDA Expands Durvalumab Label to Operable Lung Cancer
4.
New guidelines expand access to lung cancer screening, but gaps remain in reaching rural and uninsured populations
5.
There is a 40% reduction in the risk of 9 cancers with good cardiorespiratory fitness.
1.
The Architect's Dilemma: Remodeling the Tumor Microenvironment for a New Era of Cancer Immunotherapy
2.
Harnessing Artificial Intelligence in Oncology: Innovations in Diagnosis, Treatment, and Patient Care
3.
Unveiling the Hidden Benefits of Lymphedema Treatment
4.
IGF2BP1 in Blood Disorders: Therapeutic Potential and Comprehensive Functional Insights
5.
Florinef: Understanding Its Uses and Side Effects
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
3.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
4.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation